(19)

(11)

EP 4 739 335 A1

(12)

(43) Date of publication: 13.05.2026 Bulletin 2026/20 (21) Application number: 24836512.4 (22) Date of filing: 01.07.2024

(51) International Patent Classification (IPC):  A61K 38/33(2006.01) A61K 9/127(2025.01) A61K 9/72(2006.01) C08B 37/08(2006.01) A61K 47/36(2006.01) A61K 9/14(2006.01) A61K 31/722(2006.01) (52) Cooperative Patent Classification (CPC): A61K 9/0073; A61K 31/722; C08B 37/003; C08L 5/08; A61K 38/08; A61K 9/0043; A61K 9/5146   C-Sets: A61K 31/722, A61K 2300/00; A61K 38/08, A61K 2300/00; (86) International application number: PCT/US2024/036371 (87) International publication number: WO 2025/010224 (09.01.2025 Gazette 2025/02)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: GE KH MA MD TN (30) Priority: 03.07.2023 US 202363524764 P (71) Applicant: Virpax Pharmaceuticals Inc. Berwyn, PA 19312 (US)	(72) Inventors: UCHEGBU, Ijeoma Berwyn, PA 19312 (US) SCHATZLEIN, Andreas Berwyn, PA 19312 (US) MACK, Anthony Berwyn, PA 19312 (US) MATHIAS, Sheila Berwyn, PA 19312 (US) (74) Representative: Avidity IP  Future Business Centre Cambridge Campus Kings Hedges Road Cambridge CB4 2HY Cambridge CB4 2HY (GB)